Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mesoblast (MESO – Research Report) and Immatics (IMTX – Research Report).
Mesoblast (MESO)
Chardan Capital analyst Keay Nakae maintained a Sell rating on Mesoblast today and set a price target of $2.50. The company’s shares closed last Thursday at $3.41, close to its 52-week low of $3.23.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mesoblast with a $9.25 average price target.
See the top stocks recommended by analysts >>
Immatics (IMTX)
Jefferies analyst Kelly Shi maintained a Buy rating on Immatics yesterday and set a price target of $20.00. The company’s shares closed last Thursday at $7.79.
According to TipRanks.com, Shi is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Immatics is a Strong Buy with an average price target of $20.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MESO:
- J.P. Morgan Sticks to Their Hold Rating for DoorDash (DASH)
- J.P. Morgan Thinks Phreesia’s Stock is Going to Recover
- Summit Materials (SUM) Receives a Buy from J.P. Morgan
- J.P. Morgan Maintains Their Buy Rating on Corporate Office Properties (OFC)
- Getty Realty (GTY) Gets a Hold Rating from J.P. Morgan
